Pacira BioSciences Inc (PCRX) Company Profile & Statistics

Pacira BioSciences Inc
PCRX
(Nasdaq - US)
N/A
20.04
+0.06 (+0.30%)
in:usd•As of: Jul 26, 2024 15:59 UTC -4
Open
20.10
High
20.57
Low
19.97

About Pacira BioSciences Inc

CEO

Frank D. Lee

Headquarters

5401 west kennedy boulevard, suite 890

tampa, fl 33609, united states

Auditor

KPMG LLP

Employees

712

Share Holders

Website

www.pacira.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.

Pacira BioSciences Inc Statistics

Valuation Measures

Market Capitalization ²	932.86M
Enterprise Value	1.27B
Enterprise Value/EBITDA (ttm)	7.00
Price to Earnings Ratio (ttm)	8.96
Price to Book (mrq)	1.06
Price to Sales (ttm)	1.38
Price to Cash (ytd)	5.12

Profitability

Gross Margin (ttm)	73.15%
Operating Margin (ttm)	16.20%
Profit Margin (ttm)	10.23%
Return on Equity (ttm)	12.98%
Return on Invested Capital (ttm)	5.16%
Return on Assets (ttm)	7.08%

Income Statement

Revenue (ttm)	681.75M
Revenue Per Share (ttm)	14.65
Gross Profit (ttm)	498.69M
EBITDA (ttm)³	181.22M
Net Income Avi to Common (ttm)	70.47M
Diluted EPS (ttm)	1.43

Share Statistics

Beta (5Y Monthly)	0.88
52-Week Change	-44.72%
S&P500 52-Week Change	19.54%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	46.55M
Dividend Yield	0.00%
Float ⁴	43.57M
% Held by Insiders	6.40%
% Held by Institutions	99.73%

Balance Sheet

Total Cash (mrq)	325.89M
Total Cash Per Share (mrq)	7.00
Total Debt (mrq)	520.33M
Total Debt/Equity (mrq)	58.32%
Current Ratio (mrq)	5.81%
Quick Ratio (mrq)	4.78%
Book Value Per Share (mrq)	19.18

Cash Flow

Operating Cash Flow Per Share (ytd)	0.94
Free Cash Flow (ytd)	46.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Pacira BioSciences Inc

Trade With A Regulated Broker